Search results for

We welcome Reto Ferrari-Visca, Jeremy Reichlin and Alexander Wherlock to our partnership.

Nader, Hayaux & Goebel (NHG) is pleased to announce the promotion of Fernando Castillo and Jorge Bojalil to Partners, effective January 1, 2026.

Horten and DAHL are merging to become HortenDahl. By joining forces, the firms will achieve a truly unique position in the Danish legal market – with almost 250 years of combined history, strong local roots, an international outlook and the capabilities to provide broader and deeper advice to both private and public-sector clients.

Following on from William Fry's recent new partner appointments, the Firm is delighted to announce the promotion of several key individuals who have demonstrated exceptional dedication and expertise in their respective fields.

Karanovic & Partners is pleased to announce the promotion of three distinguished team members to the position of Senior Partner,n effective 1 January 2026.

On behalf of KAMUT Enterprises of Europe (BV, “KEE”), the owner of the trademark for the global premium grain brand “KAMUT,” Kim & Chang prevailed in the lawsuit on the merits, the preliminary injunction action, and the IPTAB trials in Korea. “KAMUT” is a brand for Khorasan wheat products that has been used and managed globally by KEE since its trademark was registered in the US in 1990. It was first imported into Korea in 2015 and has since gained high recognition in the health food market.

The Capital Markets team of Elias Neocleous & Co LLC has successfully advised on the sale of existing shares by Rangeglow Limited, a Cyprus-based entity, in connection with the initial public offering (IPO) of Cris-Tim Family Holding on the Regulated Market, Premium Category of the Bucharest Stock Exchange raising RON 454.35 million.

Omnidocs Group ApS (Denmark), a portfolio company of Main Capital Partners and a provider of document creation software, has acquired all shares in officeatwork AG. officeatwork AG is a provider of document creation solutions.

On December 21, 2025, Windward Bio Group AG, a Swiss-based private, clinical-stage biotechnology company committed to improving outcomes for people living with advanced immunological diseases, announced a licensing agreement between its affiliate, LE2025 Therapeutics AG, and Qyuns Therapeutics Co., Ltd. for the development and commercialization of WIN027 (also known as QX027N), a potential best-in-disease, long-acting bispecific antibody targeting TSLP and IL-13.

Partners at JunHe, Morrison Foerster and White & Case discuss the forces that shaped dealmaking across China, Japan and Hong Kong this year